That is why my team and I work hard each day to challenge the status quo of this disease. We refuse to accept the current state of affairs, and neither should you.
In the same way, we rallied together decades ago to challenge breast cancer, we must now rally to challenge pancreatic cancer. The progress witnessed in breast cancer survival rates, from the struggles of the past to the triumphs of today, serves as an indomitable reminder that a united collective can achieve lasting change.
Raising sympathy does not create survivors, sorry does not save lives, action does. At Pancreatic Cancer Canada, we are laser-focused on raising survival rates and on providing the resources and support pancreatic cancer patients and their families need.
We lead the way by investing in innovative research into pancreatic cancer. Through our investments in genomic testing and clinical trials, we have uncovered valuable insights and developed personalized treatment options. Our groundbreaking PASS-01 clinical trial, supported by renowned organizations, aims to advance personalized medicine for late-stage patients.
In addition to research funding, we provide vital peer support through our partnership with Wellspring. Recognizing the far-reaching impact of a pancreatic cancer diagnosis, we have expanded our collaboration to reach more Canadians in need.